Lab. di Genetica Molecolare, Istituto Giannina Gaslini, Largo Gerolamo Gaslini 5, 16147 Genoa, Italy.
Am J Physiol Cell Physiol. 2010 Apr;298(4):C866-74. doi: 10.1152/ajpcell.00404.2009. Epub 2010 Jan 6.
Cystic fibrosis (CF) is caused by mutations in the CFTR chloride channel. Deletion of phenylalanine 508 (F508del), the most frequent CF mutation, impairs the maturation and gating of the CFTR protein. Such defects may be corrected in vitro by pharmacological modulators named as correctors and potentiators, respectively. We have evaluated a panel of correctors and potentiators derived from various sources to assess potency, efficacy, and mechanism of action. For this purpose, we have used functional and biochemical assays on two different cell expression systems, Fischer rat thyroid (FRT) and A549 cells. The order of potency and efficacy of potentiators was similar in the two cell types considered, with phenylglycine PG-01 and isoxazole UCCF-152 being the most potent and least potent, respectively. Most potentiators were also effective on two mutations, G551D and G1349D, that cause a purely gating defect. In contrast, corrector effect was strongly affected by cell background, with the extreme case of many compounds working in one cell type only. Our findings are in favor of a direct action of potentiators on CFTR, possibly at a common binding site. In contrast, most correctors seem to work indirectly with various mechanisms of action. Combinations of correctors acting at different levels may lead to additive F508del-CFTR rescue.
囊性纤维化(CF)是由 CFTR 氯离子通道的突变引起的。苯丙氨酸 508 缺失(F508del)是最常见的 CF 突变,它会损害 CFTR 蛋白的成熟和门控。这种缺陷可以在体外通过分别称为校正剂和增强剂的药理学调节剂来纠正。我们已经评估了一组来自不同来源的校正剂和增强剂,以评估它们的效力、功效和作用机制。为此,我们使用了两种不同的细胞表达系统(Fischer 大鼠甲状腺(FRT)和 A549 细胞)的功能和生化测定。在考虑的两种细胞类型中,增强剂的效力和功效顺序相似,苯甘氨酸 PG-01 和异噁唑 UCCF-152 分别是最有效和最无效的。大多数增强剂对两种突变也有效,G551D 和 G1349D,它们仅引起门控缺陷。相比之下,校正剂的效果受到细胞背景的强烈影响,许多化合物仅在一种细胞类型中起作用的情况极为极端。我们的发现支持增强剂对 CFTR 的直接作用,可能在共同的结合位点。相比之下,大多数校正剂似乎通过不同的作用机制间接起作用。作用于不同水平的校正剂的组合可能导致 F508del-CFTR 拯救的加和。